tci 2013 biobasque and the basque biocluster

BioBasque and the Basque BioClusterCristina Oyón

Breakout Session: Clusters and smart specialisation strategies: design and implementation

5 September 2013

From the different theoretical ways of smart diversification, could the radical foundation of a science based new industrial activity be a sound lever for productive transformation?

Source: The Basque Country Competitiveness Report, 2013 - Orkestra

The Question

The BioRegion

The Strategy

• First strategy specifically designed (2001-2002) to promote lifesciences in Spain

• Aim: to develop a new business sector in the Basque Country reated to biosciences

• Integrated approach built around three axis: knowledgegeneration, business development, dynamisation

• Mission: to establish a biocluster capable of competinginternationall

• Cuantitative objectives: 40 new companies, 3.000 new jobs

• Chosen as RegioStars 2011 Awards (EU) finalist, among 66 initiatives from 18 countries, awards to most innovativeregional projects which have received funding from the EU regional/ cohesion policy

The Ecosystem

The Research Subsystem

Micro-nano-bio convergence

The Research Subsystem

The Molecular Imaging Facility

The Health Subsystem

The Health Subsystem

DEMOTEK: medical devices effectiveness demonstration unit

The Innovation Support Subsystem

The Technology Transfer Process

The Business Evolution

now2001

The Government Support

Source: The Basque Country Competitiveness Report, 2013 - Orkestra

The Budget

Rough figures of public investment in 2012

Knowledge generation

~20 M€

Sector dynamisation

~0,5 M€

Business development

~5 M€

The Outcome

18

Service Provision

Diagnostics

Therapeutics

Other

Antigens, antibodies one-stop shop

Early drug discovery in-vivo

Food, environmental safetyDrug development services

Drug screening & analysis

Clean labs, bio-safety

Engineers and consultants agri-food

Bromatology lab

Drug production support

Ophthalmological sanitary products

Polymeric dispersion µ-beads

Bio-software systems

Natural chem. fungicides (crops)Cell-based assays (drug discovery)

Metabolomic Dx

Vaccines, allergology

Drug development (CNS)

Regenerative medicine

Full-cycle Pharma

Tissue engineering, cell therapy

Biotech cosmetics

Nanomedicines (biocompatible nanoparticles)Drug development, distribution

Non-invasive Dx (ophthalmology )

Genetic Dx methods

Genomic IVD tests

In-vitro Dx tests Dx & Tp animal health

The Outcome

The Outcome

BioBasque is recognized as a BioRegion at national and international scale. We are the 4th community in Spain regarding nr of biotechs, accounting for the 9%, well above the 6% of Spanish GDP that supposes the Basque economy.

In 2007-2011 the nr of biotechs has been multiplied by 1,4. The sector employs directly 1.600 persons in R&D, representing 5,8% of total employment in R&D. The R&D personnel accounts for the 50% of total employment

The sector invoices more than 300 M€. 57% of biotechs have increased its invoicing in the period 2007-2011. 31% have maintained it.

60% of biotechs are less than 10 years old. 90% of them are internationalized

The Future

TRANSVERSAL CAPACITIES

• Biosciences

• Nanosciences

• Advanced manufacturing

MARKETS

• Movility & Transport

• Digital World

• Science Industry

• Ageing / Health

• Energy

Bio-NanoSciences

SmartManufacturing

Energy

EXISTING PRIORIZITATION

(PCTI 2015)

REFLECTION PROCESS

METAPRIORITIES

REFLECTION PROCESS

PILOTPROJECTS

Source: The Basque Country Competitiveness Report, 2013 - Orkestra

Cristina Oyón

Head of Strategic Initiatives, SPRI

cristina@spri.es

biobasque@spri.es

www.biobasque.org